Eplerenone (Inspra) (25 mg tablet and 50 mg tablet) : as an adjunct to standard therapy to reduce the risk of cardiovascular mortality and hospitalization for heart failure in patients with NYHA class II systolic chronic heart failure and left ventricular systolic dysfunction

The objective of this systematic review was to evaluate the beneficial and harmful effects of eplerenone 25 mg to 50 mg daily for the treatment of patients with New York Heart Association (NYHA) class II systolic chronic heart failure (HF) and left ventricular systolic dysfunction

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2014, [2014]
Series:Common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:The objective of this systematic review was to evaluate the beneficial and harmful effects of eplerenone 25 mg to 50 mg daily for the treatment of patients with New York Heart Association (NYHA) class II systolic chronic heart failure (HF) and left ventricular systolic dysfunction
Item Description:Title from Bookshelf title caption
Physical Description:1 online resource illustrations